WP5: Cost-effectiveness analysis

Thank you for your interest. The I-MOVE+ project (2015-2018) is over, and this website will no longer be updated. However, activities to monitor vaccine effectiveness in Europe are ongoing and can be found on the I-MOVE and SpiDnet websites for influenza (coming soon) and pneumococcal disease (https://sites.google.com/a/epiconcept.fr/ipd-surveillance/)

Description of the Work Package

WP5 is focused on modeling and the development of cost-effectiveness models for pneumococcal and influenza vaccination to prevent disease in the elderly. Cost-effectiveness models are frequently used to support  evidence  based  decision  making,  particularly  for  vaccination.  Therefore  to  assure  and  promote  the impact of our working group on national vaccine policy in participating countries the results in work packages 2, 3, and 4 on the estimated vaccine  effectiveness and impact of influenza and pneumococcal vaccination will be applied in cost-effectiveness models together with disease burden estimation to determine prevented disease burden in the elderly and saved costs.

Objectives of the work package will be achieved through a Scientific Working Group of modelers, health economists and epidemiologists from the consortium (WP lead PHE, THL, RIVM, RKI, HPS, University Surrey) that will work very closely with WPs 2-4. 

Attendees to the Work Package 5 Technical Meeting in January 2016, held in London

Useful links

Leader: Public Health England

  • HPS, Scotland
  • ISPLN, Navarra, Spain
  • ISanté Publique France, France
  • PHE, England
  • RCGP, England
  • RIVM, Netherlands
  • RKI, Germany
  • FHI, Norway
  • INSA, Portugal
  • THL, Finland
  • SSI, Denmark

Access to restricted area for Work Package 5